OR WAIT 15 SECS
The investment builds on a collaboration the companies entered into in 2007 for various biomanufacturing projects.
On Nov. 29, 2018, Tosoh Bioscience, a provider of liquid chromatography products, announced that it has completed an equity investment in Semba Biosciences, a US-based provider of instruments, reagents, and methods for purification of biomolecules and chemicals, with the intention of acquiring full ownership of the company. Tosoh Bioscience is a US-based subsidiary of Tosoh Corporation in Japan.
The transaction was approved by both companies’ boards of directors. “Our respective technologies fit perfectly together to provide an integrated solution for bioprocess research, development, and continuous manufacturing,” said Dr. Robert Mierendorf, president of Semba Biosciences, in a company press release.
The two companies have been collaborating on various downstream biomanufacturing projects since 2007, combining Semba Biosciences’ advanced simulated moving bed (SMB) technology with Tosoh Bioscience’s resins.
Source: Tosoh Bioscience